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Summary
 
The dual specific kinase SAPK/ERK1 kinase (SEK1; mitogen-activated protein kinase kinase
 
4/Jun NH
 
2
 
 terminal kinase [JNK] kinase) is a direct activator of stress-activated protein kinases
([SAPKs]/JNKs) in response to CD28 costimulation, CD40 signaling, or activation of the ger-
 
minal center kinase. Here we show that SEK1
 
2
 
/
 
2
 
 recombination-activating gene (RAG)2
 
2
 
/
 
2
 
chimeric mice have a partial block in B cell maturation. However, peripheral B cells displayed
normal responses to IL-4, IgM, and CD40 cross-linking. SEK1
 
2
 
/
 
2
 
 peripheral T cells showed
decreased proliferation and IL-2 production after CD28 costimulation and PMA/Ca
 
2
 
1
 
 iono-
phore activation. Although CD28 expression was absolutely crucial to generate vesicular sto-
matitis virus (VSV)-specific germinal centers, SEK1
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 chimeras mounted a protective
antiviral B cell response, exhibited normal IgG class switching, and made germinal centers in
response to VSV. Interestingly, PMA/Ca
 
2
 
1
 
 
 
ionophore stimulation, which mimics TCR–CD3
and CD28-mediated signal transduction, induced SAPK/JNK activation in peripheral T cells,
but not in thymocytes, from SEK1
 
2
 
/
 
2
 
 mice. These results show that signaling pathways for
SAPK activation are developmentally regulated in T cells. Although SEK1
 
2
 
/
 
2
 
 
 
thymocytes
failed to induce SAPK/JNK in response to PMA/Ca
 
2
 
1
 
 ionophore, SEK1
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 thy-
mocytes proliferated and made IL-2 after PMA/Ca
 
2
 
1
 
 ionophore and CD3/CD28 stimulation,
albeit at significantly lower levels compared to SEK1
 
1
 
/
 
1
 
RAG2
 
2
 
/
 
2
 
 thymocytes, implying that
CD28 costimulation and PMA/Ca
 
2
 
1
 
 ionophore–triggered signaling pathways exist that can
mediate proliferation and IL-2 production independently of SAPK activation. Our data pro-
vide the first genetic evidence that SEK1 is an important effector molecule that relays CD28
signaling to IL-2 production and T cell proliferation.
 
D
 
istinct and evolutionarily conserved signal transduc-
tion cascades mediate survival or death in response to
developmental and environmental cues. Multiple stimuli
for differentiation and cell growth activate the mitogen-
activated protein kinases (MAPKs)
 
1
 
, also known as the ex-
tracellular signal-regulated kinases ERK1 and ERK2 (1–4),
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Abbreviations used in this paper:
 
 ERK, extracellular signal-regulated kinase;
ES, embryonic stem; GCK, germinal center kinase; ICAM-1, intercellu-
lar adhesion molecule 1; JNK, Jun NH
 
2
 
 terminal kinase; MAPK, mito-
gen-activated protein kinase; MEK, MAPK/ERK kinase; MKK4, MAPK
kinase; RAG, recombination-activating gene; SAPK, stress-activated pro-
tein kinase; SEK, SAPK/ERK kinase; sIg, surface Ig; VSV, vesicular sto-
matitis.
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which translocate to the nucleus and regulate the activity of
transcription factors (5). MAPKs are activated by the phos-
phorylation of a threonine and a tyrosine residue mediated
by the dual specificity MAPK kinases MAPK/ERK kinase
(MEK)1 and MEK2, which relay Ras and Raf signal trans-
duction to MAPK activation (6–8).
A second signaling cascade exists in all cells that leads to
the activation of stress-activated protein kinases (SAPKs) or
Jun NH
 
2
 
 terminal kinase (JNKs; 9,10). The SAPK signaling
cascade is parallel and independent from MAPK activation
(11, 12). SAPKs/JNKs are activated in response to a variety
of cellular stresses such as changes in osmolarity and metab-
olism, DNA damage, heat shock, ischemia, inflammatory
cytokines, or ceramide (13–18). Activated SAPKs/JNKs
phosphorylate c-Jun, which leads to activation of the tran-
scriptional complex AP-1 (19). SAPKs/JNKs are activated
by the phosphorylation of tyrosine and threonine residues,
which is catalyzed by the dual specificity kinase SAPK/
ERK kinase (SEK)1 (also known as MAPK kinase [MKK4]
and JNK kinase; 20–22). In addition to SEK1, a novel
SAPK activator (SEK2 or MKK7) has been genetically
identified but has not been cloned yet (23).
It has been proposed from transfection studies with dom-
inant negative signaling mutants that the SEK1
 
®
 
SAPK/
JNK
 
®
 
c-Jun signaling cascade is a common intracellular
pathway required for the induction of apoptosis in response
to many types of cellular stresses (16–18, 24–28). However,
recent genetic evidence suggests that SEK1 and SEK1-
mediated SAPK activation have no role in the induction of
cell death in lymphocytes, but rather protect T cells from
CD95 (FAS) and CD3-mediated apotosis (23). The SAPK/
JNK signaling cascade is also triggered by certain growth stim-
ulating factors and phorbol esters (9, 14, 29, 30). In B cells,
SEK1 and SAPK are activated in response to CD40 cross-
linking (31, 32) and by the human STE20 homologue germi-
nal center kinase (GCK) (33). The prominent expression of
GCK in germinal centers (34) suggested that the GCK/SAPK
pathway might be important for B cell differentiation or
activation. Moreover, biochemical studies in T cells indi-
cated that SAPKs/JNKs are involved in the integration of
TCR–CD3 and CD28 costimulatory signals required for
proliferation and IL-2 production (29, 35). Failure to activate
SAPKs/JNKs in T cells may result in clonal anergy (36, 37).
To determine the role of SEK1 in B cell function and
CD28-mediated costimulation, we reconstructed T (23)
and B cell development in 
 
SEK1
 
 gene–deficient chimeras
using recombination-activating gene (RAG)2 blastocyst com-
plementation. We show that SEK1 is important for CD28-
mediated costimulation for T cell proliferation and IL-2
production. B lymphocyte development was partially im-
paired. However, peripheral B cells displayed normal re-
sponses to IL-4 and to IgM and CD40 cross-linking, and
exhibited normal IgG class switching after vesicular stoma-
titis virus (VSV) infections. Moreover, we show that
CD28, but not SEK1, is crucial for VSV-specific germinal
center formation. Interestingly, using the same activation
regimen, i.e., PMA plus Ca
 
2
 
1
 
 ionophore which mimics
TCR–CD3- and CD28-mediated signal transduction (29),
SAPK activation was observed in peripheral T cells, but not
in thymocytes, from SEK1
 
2
 
/
 
2
 
 mice. These data provide
the first genetic evidence that SEK1-regulated stress signal
transduction has a role in CD28 costimulation for IL-2
production and proliferation. These results also show that
signaling pathways for SAPK activation are developmen-
tally regulated in T cells.
 
Materials and Methods
 
Mice.
 
The generation of embryonic stem (ES) cells homozy-
gous for the SEK1 mutation, SEK1
 
2
 
/
 
2
 
 somatic chimeras using
RAG2
 
2
 
/
 
2
 
 blastocyst complementation (23, 38), and CD28
 
2
 
/
 
2
 
mice (39) have been previously described. Since E14 ES cells are
derived from a 129/J mouse background, age-matched 129/J
mice were used as wild-type controls. T and B cells from SEK1
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 mice were tested for the SEK1 mutation using PCR
(sense primer: 5
 
9
 
-ACAGCAAATTTTGGAAACAGC-3
 
9
 
; anti-
sense primer: 5
 
9
 
-CTCCCCTACCCGGTAGAATTC-3
 
9
 
). All
data presented throughout this study were obtained from two in-
dependently derived SEK1
 
2
 
/
 
2
 
 ES cell clones (No. 1-6 and No.
1-21), and all results were comparable between them. If not oth-
erwise stated, all mice used for experiments were between 6 and
10 wk old. Mice were kept under pathogen-free conditions in accor-
dance with guidelines of the Canadian Medical Research Council.
 
Immunocytometry.
 
Single cell suspensions from thymocytes,
spleen cells, mesenteric lymph node cells, and bone marrow cells
from SEK1
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 chimeric, SEK1
 
1
 
/
 
1
 
RAG2
 
2
 
/
 
2
 
 chimeric,
RAG2
 
2
 
/
 
2
 
, and 129/J mice were prepared as described (40), re-
suspended in immunofluorescence-staining buffer (PBS, 4% FCS,
0.1% NaN
 
3
 
) and incubated with appropriate Abs. The following
mAbs were used: anti-CD4 (FITC-, or PE-labeled), anti-CD8
(FITC-labeled, PE-labeled, or biotinylated), anti–TCR
 
a
 
/
 
b
 
(FITC-, or PE-labeled), anti–CD3-
 
e
 
 (FITC-labeled), anti-B220
(FITC-labeled, PE-labeled, or biotinylated), anti-CD43 (FITC-
labeled), anti–CD25/IL-2R-
 
a
 
 (biotinylated), anti-H2K
 
b
 
 (FITC-
labeled), anti-CD44 (PE-labeled), anti-FAS (PE-labeled, or bioti-
nylated), anti–intercellular cell adhesion molecule 1 (ICAM-1;
biotinylated); anti-CD23 (PE-labeled), anti-CD28 (PE-labeled),
anti–CTLA-4 (PE-labeled), anti-CD69 (FITC-labeled), anti-CD40L
(gp39; biotinylated) (all above Abs were from PharMingen, San
Diego, CA); anti–surface (s)IgM (clone B67; FITC-labeled, gift
of C. Paige, Ontario Cancer Institute, Toronto, Canada), anti-
sIgD (PE-labeled; gift of C. Paige), and anti-CD40 (FITC-
labeled; Serotec, Toronto, Canada). All staining combinations
were as indicated in the figure and table legends. Biotinylated Abs
were visualized using Streptavidin-RED670 (Life Technologies,
Burlington, Canada). Samples were analyzed using a FACScan
 
Ò
 
(Becton Dickinson, Mountain View, CA).
 
Cell Sorting.
 
Bone marrow cells were isolated from RAG2
 
2
 
/
 
2
 
,
SEK1
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 chimeric, SEK1
 
1
 
/
 
1
 
RAG2
 
2
 
/
 
2
 
 chimeric, and
129/J control mice and double stained for CD43 and B220 expres-
sion using anti-CD43-FITC and anti-B220-PE. CD43
 
1
 
B220
 
1
 
 and
B220
 
1
 
CD43
 
2
 
 bone marrow B cell polulations (Fig. 2) were
sorted using a FACS
 
Ò
 
 power sorter (FACS
 
Ò
 
 Vantage). In all ex-
periments, postsorting purity of CD43
 
1
 
B220
 
1
 
 and B220
 
1
 
CD43
 
2
 
populations was 
 
.
 
98%. Sorted cells were analyzed for the SEK1
mutation using PCR (see above).
 
B and T Cell Stimulation Assays.
 
Lymph node T cells were
negatively enriched from lymph nodes of SEK1
 
2
 
/
 
2
 
RAG2
 
2
 
/2
chimeric and SEK11/1RAG22/2 chimeric mice using affinity
columns (R&D Sys. Inc., Minneapolis, MN) to avoid receptor943 Nishina et al.
cross-linking during the purification process. Purified (.95%) T
cells (104) and freshly isolated thymocytes were placed into
round-bottom 96-well plates (Costar, Fisher Scientific, Union-
ville, Canada) in freshly prepared IMDM (10% FCS, 1025 M b
mercaptoethanol) and activated with PMA (12.5 ng/ml) plus
Ca21 ionophore A23617 (100 ng/ml), plate-bound anti–CD3-e
(clone 145-2C11, hamster IgG; PharMingen), soluble anti–CD3-e
(clone 145-2C11), and soluble anti-CD28 (clone 37.51, hamster
IgG; gift of Dr. J. Allison, University of California, Berkeley,
CA). PMA/Ca21 ionophore and mAbs were added at optimal
concentrations determined in pilot studies. For CD3 cross-link-
ing, plates were coated overnight (48C) with 10 mg/well of rabbit
anti–hamster IgG (Jackson Labs., West Grove, PA), and subse-
quently with anti–CD3-e (378C for 2 h, clone 145-2C11).
B cells were purifed from SEK12/2RAG22/2 chimeric and
SEK11/1RAG22/2 mice as described (41). In brief, erythrocyte-
free spleen cells were treated with anti-Thy1.2, anti-CD4, and
anti-CD8 followed by the addition of guinea pig complement
(Cedarlane Hornby, Canada). The remaining cells were added to
a Percoll gradient (2.5 3 106/10 ml gradient). Recovered cells
represented 10–30% of the cells placed on the gradient. FACSÒ
analysis revealed that these cells were .90% sIg1. Cells were
placed into a round-bottom 96-well plate (Costar, Fisher Scien-
tific) in IMDM. B cells were then activated using soluble anti-Igm
(mAb clone B76), recombinant murine IL-4 (Genzyme, Cam-
bridge, MA), soluble anti-CD40 (Serotec), and LPS (Sigma Chemi-
cal Co., St. Louis, MO). Optimal conditions were determined in
preliminary titration experiments. B and T cells were harvested at
1–4 d after a 12-h pulse with 1 mCi [3H]thymidine/well. T cell
culture supernatants were assayed in triplicate for IL-2 by ELISA
(Genzyme).
CD40 Cross-linking. For CD40-mediated upregulation of
ICAM-1 and CD23 (42), purified B cells were activated with
anti-CD40 (2 mg/ml; Serotec) in the absence or presence of IL-4
(50 U/ml) in IMDM (10% FCS, 378C). After 24 h of activation,
cells were harvested and triple stained with Abs reactive against
B220 (PE), sIgM (FITC), and ICAM-1 (biotin) or CD23 (biotin).
Biotinylated Abs were visualized using Streptavidin–RED670 and
staining of cells was analyzed using a FACScanÒ.
Detection of Ig-subclasses. Sera were collected from 6-wk-old
individual SEK12/2RAG22/2 and SEK11/1RAG22/2 chimeric
mice. The concentrations of Ig subclasses were determined by
ELISA with isotype-specific, alkaline phosphatase–conjugated
Abs (Southern Biotechnology Assoc. Birmingham, AL). Serum Ig
concentrations were determined by fivefold serial dilutions and
calculated according to standard charts as described previously (39).
VSV Infections and Detection of VSV-neutralizing Abs. Mice were
immunized with VSV-Indiana (2 3 106 PFU, intravenously). Af-
ter 4, 8, and 12 d, sera were collected and neutralizing IgM and
IgG Ab titers determined as described (43). In brief, 1:2 dilutions
of 40-fold prediluted serum were incubated with VSV for 90
min. The presence of remaining infectious virus was determined
by incubating the VSV serum samples with fibroblasts for another
24 h. Serum dilutions that reduced the number of viral plaques by
50% were taken as specific titers. IgG titers were determined after
preincubation of sera with 2b mercaptoethanol, a procedure that
eliminates IgM (43).
Germinal Center Formation and Immunohistochemistry. To deter-
mine formation of germinal centers, 6 wk old SEK12/2RAG22/2
and SEK11/1RAG22/2 chimeric mice and CD282/2 mice were
infected with VSV-Indiana as described above. Spleens from
VSV-infected animals were harvested 12 d after the intial infec-
tion, frozen in liquid nitrogen, and processed for cryosections.
Cryostat sections (5 mm) were fixed in acetone (10 min). Sections
were incubated with PNA (diluted 1:200) and bound PNA was
detected by rabbit anti-PNA Abs (diluted 1:300; DAKO, Glos-
trup, Denmark). CD4 was detected by the rat mAb YTS191.
Binding of primary Abs was detected by alkaline phosphatase-
labeled goat Abs to rabbit or rat Ig (1:80 dilution; Jackson Labs.)
followed by alkaline phosphatase-labeled donkey Abs against goat
Ig (1:80 dilution; DAKO). Alkaline phosphatase was visualized us-
ing Napthol AS-BI phosphatase and New Fuchsin as a substrate,
which yields a red precipitate. Endogenous alkaline phosphatase
activity was blocked by levamisole (44).
VSV-specific B cells were detected as described (44). In brief,
dehydrated tissue sections were overlaid with a solution of UV-
inactivated VSV (3 3 106 PFU/ml) for 4 h. Specifically bound
virus was detected by incubation with polyclonal rabbit anti–VSV
Indiana serum (diluted 1:1,500), followed by alkaline phos-
phatase-labeled goat Abs to rabbit Ig and rabbit anti–goat Ig (di-
luted 1:80; Jackson Labs.). Napthol AS-BI phosphatase and New
Fuchsin were used to develop the color reaction (44).
SAPK/JNK Activities. Thymocytes and purified lymph node
T cells (5 3 106) were activated with PMA (50 ng/ml) and the
Ca21 ionophore A23617 (1 mg/ml) as previously described (23,
29). Cells were lysed in ice-cold lysis buffer (10 mM NaCl, 20
mM Pipes, pH 7.0, 0.5% NP-40, 5 mM EDTA, 0.05 b mercap-
toethanol, 100 mM Na3VO4, 50 mM NaF, 20 mg/ml leupeptin,
and 1 mM benzamidine). Cleared lysates were adjusted to equal
protein concentrations (BioRad Protein Assay; Bio Rad Labs.,
Hercules, CA). SAPKs/JNKs were immunoprecipitated (1 h,
48C) using polyclonal rabbit anti-SAPK/JNK Abs reactive against
all SAPK/JNK isoforms (10). Immune complexes were harvested
on protein A–Sepharose beads. For kinase assays, immune com-
plexes were washed three times with PBS-Triton buffer (150 mM
NaCl, Na2HPO4, 4 mM NaH2PO4, 0.1% Triton X-100, 100
mM Na3VO4, 50 mM NaF, 20 mg/ml leupeptin, and 1 mM ben-
zamidine). SAPK/JNK kinase assays were performed in 20 ml of
kinase buffer (10 mM MgCl2, 50 mM Tris-Cl, pH 7.5, 1 mM
EGTA, pH 7.5) in the presence of 1.2 mCi [32P]g-ATP and 5 mg
glutathione-S-transferase–c-Jun as in vitro substrate (308C, 30
min). The reaction was stopped by the addition of 23 SDS sam-
ple buffer. Phosphoproteins were separated by SDS-PAGE and
visualized by autoradiography as described (10). The levels of ex-
pression of SAPK/JNKs in thymocytes and lymph node cells
were determined by immunoblotting using goat anti-JNK1 and
rabbit anti-JNK2 polyclonal Abs (both from Santa Cruz Biotech-
nology Inc., Santa Cruz, CA; 23).
Results
Impaired Proliferation and IL-2 Production of SEK12/2 Periph-
eral T Cells.  Recent biochemical studies implied that the
SAPK/JNK signaling pathway is operating in T cells, and
that cell proliferation and IL-2 production induced by CD28
costimulation may be mediated via SAPK/JNK (29, 36,
37). SEK12/2RAG22/2 chimeric mice have a smaller thy-
mus, but normal numbers of peripheral T cells (Table 1; refer-
ence 23). To test the role of SEK1 in CD28 costimulation,
lymph node T cells were cultured in anti–CD3-e Ab-coated
plates in the absence or presence of various concentrations of
soluble anti-CD28 Abs. Whereas SEK12/2RAG22/2 and
SEK11/1RAG22/2 T cells reponded in the same way to
CD3-e activation alone, CD28-mediated upregulation of944 SEK1 in CD28 Costimulation
proliferation and IL-2 production were significantly re-
duced in SEK12/2 T cells (Fig. 1, A and B). Reduced pro-
liferation and IL-2 production were also observed in
SEK12/2 T cells after stimulation with PMA/Ca21 iono-
phore (Fig. 1, A and B), which mimic TCR–CD3- and
CD28-mediated signal transduction (29, 45).
Since the proliferative response to plate-bound anti–
CD3-e Abs alone was still very vigorous (Fig. 1 A), we an-
alyzed T cell activation in response to suboptimal concen-
trations of soluble anti–CD3-e Abs. As shown in Fig. 1, C and
D, proliferation and IL-2 production of SEK12/2RAG22/2
and SEK11/1RAG22/2 chimeric T cells were minimal af-
ter stimulation with soluble anti–CD3-e alone. Although
the addition of anti-CD28 greatly enhanced the prolifera-
tion and IL-2 production of SEK11/1RAG22/2 T cells,
SEK12/2RAG22/2 T cells were significantly impaired in
proliferation and IL-2 production (Fig. 1, C and D). It
should be noted that freshly isolated T cells from SEK12/2
mice displayed upregulated expression of CD28, but nor-
mal surface expression of the TCR-a/b–CD3-e complex,
IL-2R-a chain (CD25), CD69, and adhesion molecules
such as ICAM-1 (not shown). These data provide the first
genetic evidence that SEK1 plays an important role in T
cell proliferation and IL-2 production in transmitting
CD28 signals to downstream effector molecules.
Partial Defect in B Cell Maturation. To determine the ef-
fect of the SEK1 mutation on B cell development, single
cell suspensions from spleen, lymph nodes, and bone mar-
row of SEK12/2RAG22/2 chimeric, SEK11/1RAG22/2
chimeric, RAG22/2, and control 129/J mice were stained
with mAbs against B lineage–specific markers (Fig. 2, Table
1). The bone marrow of 129/J mice contained a relatively
low number (12%) of B2201CD431 pro–B cells and a
larger population (30%) of B2201CD432 pre–B cell pre-
cursors, and mature B cells in peripheral lymphatic organs
expressed both IgM (Fig. 2) and IgD (not shown) on the
cell surface (46). By contrast, B cell differentiation in the
bone marrow of RAG22/2 mice was blocked at the pro–B
cell stage (B2201CD431IgM2) and RAG22/2 mice did
not have any mature sIgM1 B cells (Fig. 2, Table 1; 47,
48). B-cell development and expression of sIgM and sIgD
were restored in chimeras derived from injection with pa-
rental SEK11/1 ES cells. In contrast, the relative and total
numbers of B2201CD432 bone marrow cells and B2201
sIgM1 peripheral B cells were significantly reduced in
SEK12/2RAG22/2 chimeric mice (Fig. 2, Table 1). Pe-
Table 1. T and B Cell Subpopulations in SEK12/2 Chimeric Mice
Percentages 6 SEM of positive cells per total cells
Cell subset 129/J SEK11/1 SEK12/2 RAG22/2
Thymus
CD41CD81 81.8 6 2.2 84 6 0.9 57.7 6 4.2 0
CD41CD82 11.6 6 0.8 7.7 6 0.4 27.2 6 2.8 0
CD42CD81 3.2 6 0.4 2.1 6 0.7 7.5 6 1.1 0
CD42CD82 3.5 6 0.6 6.1 6 1.0 4.8 6 0.4 100
Lymph node
CD41CD82 48.2 6 3.2 44.2 6 4.3 55.1 6 3.1 0
CD42CD81 19.0 6 2.8 20.2 6 3.7 22.1 6 1.8 0
B2201slgM1 30.5 6 1.6 26.6 6 3.5 12.0 6 3.0 0
Spleen
CD41CD82 24.0 6 5.3 22.6 6 5.3 33.2 6 2.8 0
CD42CD81 11.3 6 2.0 8.9 6 2.7 13.5 6 1.5 0
B2201slgM1 33.5 6 5.5 32.6 6 3.5 16.7 6 1.6 0
Bone marrow
B2201CD431 11.9 6 1.4 10.6 6 2.5 13.4 6 0.4 16.5 6 3.5
B2201CD432 30.8 6 2.5 34.5 6 4.5 11.6 6 1.6 ,1
B2201CD251 30.5 6 2.1 32.0 6 3.3 10.2 6 1.5 ,1
B2201CD252 10.5 6 0.9 15.1 6 2.7 12.6 6 1.2 14.6 6 4.1
Cells from thymi, mesenteric lymph nodes, spleens, and bone marrow (one femur) from 129/J (n 5 6), SEK11/1 chimeric (n 5 3), SEK12/2 chi-
meric (n 5 6), and RAG22/2 (n 5 5) mice were stained with the indicated Abs and populations determined using a FACScanÒ. Total cell numbers
(3 106 6 SEM) were: 129J: thymus, 80 6 6.3; LN, 24 6 2.2; spleen, 216 3.4; BM, 7.8 6 0.7; SEK11/1: thymus, 85 6 10.1; LN, 22 6 4.6; spleen,
32 6 3.14; BM, 8.6 6 2.5; SEK12/2: thymus, 14 6 4.1; LN, 29 6 4.2; spleen 27 6 5.3; BM, 10.6 6 0.4; RAG22/2: thymus, 1.1 6 0.2; LN, 0.76
0.2; spleen, 8.3 6 1.6; BM 9.2 6 0.9 (reference 23). Bold numbers indicate, statistically significant differences between 129/J or SEK11/1 and
SEK12/2 subpopulations (Student’s t test P ,0.05).945 Nishina et al.
ripheral B cells from SEK12/2 mice expressed normal lev-
els of CD23, CD40, CD44, ICAM-1, CD95 (FAS), and
H2Kb on the cell surface (not shown). The partial block in
the development from B2201CD431 pro–B cells to more
mature B2201CD432 pre–B cells was also observed by al-
terations in IL-2R-a chain (CD25) expression, an early B
cell maturation marker that is expressed before sIgM ex-
pression (46). Although z75% of 129/J or SEK11/1 chi-
meric B2201 bone marrow B cells expressed CD25 on the
cell surface, expression of CD25 was significantly reduced
in SEK12/2 bone marrow B cells (Table 1).
To analyze whether the observed block in B cell matura-
tion was due to the SEK1 mutation and not due to low
chimerism and contribution of RAG22/2 cells to pro–B cells,
we FACSÒ sorted B2201CD431 and B2201CD432 bone
marrow cells and analyzed the genotype of sorted cells by
PCR (Fig. 3). Both B2201CD431 pro–B cells and the
more mature B2201CD432  B cell populations in SEK12/2
chimeras contained mutant, but not wild-type SEK1 alleles
indicating that both populations were derived from SEK12/2
ES cells. These data imply that SEK1-mediated signaling
plays a role at the transition from B2201CD252CD431
pro–B cells to B2201CD251CD432  pre–B cells in the bone
marrow.
B Cell Activation. Previously it has been shown that CD40
signaling in B cells leads to the induction of SAPK/JNK ac-
tivity (31, 32). To determine the requirement of SEK1 for B
cell activation, we measured proliferation of B cells in re-
sponse to various stimuli. SEK12/2RAG22/2 B cells responded
normally to LPS, IL-4, anti-CD40, IL-4 plus anti-CD40, and
Figure 1. Proliferation (A and C) and IL-2 production (B and D) of SEK12/2 chimeric (shaded bars) and SEK11/1 chimeric (open bars) T cells. Purified
lymph node responder T cells (105 T cells/well) were activated with (A and B) plate-bound anti–CD3-e (1 mg/ml) and different concentrations of solu-
ble anti-CD28 Ab (10, 100, and 200 ng/ml) or PMA (12.5 ng/ml) plus Ca21 ionophore (100 ng/ml) (PMA 1 Ca); and (C and D) soluble anti–CD3-e
and soluble anti-CD28 Abs at the indicated concentrations. Rabbit anti–hamster Ig-coated plates without addition of anti–CD3-e (2) or CD28 (0) Abs
are shown as controls in (A and B). (C and D) data from two individual SEK12/2 and SEK11/1 chimeric mice are shown. After 24 h of stimulation, pro-
liferation was determined by [3H]thymidine uptake, and IL-2 production was determined by ELISA. Data of triplicate cultures 6 SD are shown. Similar
results were obtained after 48 and 72 h of culture (not shown). One result representative of seven independent experiments is shown.946 SEK1 in CD28 Costimulation
Igm cross-linking (Fig. 4 A). Moreover, SEK12/2RAG22/2
B cells upregulated ICAM-1 and CD23 upon activation
with anti-CD40 in the absence or presence of IL-4 (not
shown; 42). The basal serum levels for the Ig subclasses IgM,
IgG1, IgG2a, IgG2b, IgG3, and IgA were also comparable
between SEK12/2RAG22/2 and SEK11/1RAG22/2 chi-
meric mice (Fig. 4 B).
VSV Infections and IgG Class Switching. VSV infections
are exclusively controlled by neutralizing Abs (49). All
neutralizing Abs are directed against the VSV glycoprotein
which is present in a highly repetitive form in the viral en-
velope. Due to this repetitiveness, neutralizing IgM Abs are
induced in complete absence of T cell help (49). However,
the isotype switch from IgM to IgG is strictly T cell depen-
dent (50). Recently, it has also been shown that the pro-
duction of VSV-neutralizing IgG Abs is decreased in
CD282/2 mice (39). Since, SEK12/2 T cells had reduced
proliferation and IL-2 production in response to CD28 co-
stimulation (Fig. 1), but SEK12/2 B cells could be activated
normally and produced normal levels of Ig subclasses (Fig.
4), we examined T cell help and IgG class switching in
SEK12/2RAG22/2 and SEK11/1RAG22/2 mice after in-
fection with VSV (Table 2). Neutralizing serum IgM was
assessed 4 d and neutralizing serum IgG levels were mea-
sured 4, 8, and 12 d after VSV infection. VSV infection in-
duced rapid, T cell–independent IgM production, followed
by a T helper cell and CD28 costimulation-dependent IgG
response (Table 2). Surprisingly, both early IgM produc-
tion and IgG class switching were comparable between
SEK12/2RAG22/2 and SEK11/1 RAG22/2 mice (Table
2). Moreover, SEK12/2 mice survived for more than 4 wk
after infection, indicating that the B cell response was pro-
tective.
VSV-specific Germinal Center Formation. The prominent
expression of the GCK in follicular germinal centers (34)
and activation of SAPK through GCK (33) suggested that
the GCK/SAPK pathway might be important for B cell
differentiation within germinal centers. Moreover, mice
lacking CD28 (51) or CD40 (52, 53) do not develop ger-
minal centers. Since all of these receptors can activate
SAPKs/JNKs (10, 29, 31, 32), we tested whether virus-
specific germinal center formation was normal in SEK12/2
mice. Although VSV-specific germinal centers were com-
pletely absent in CD282/2 mice after challenge with VSV,
SEK12/2RAG22/2 chimeric mice developed germinal cen-
ters with normal morphology (Fig. 5) and at normal fre-
quency (Table 3). Germinal center B cells were positive for
PNA expression (Fig. 5, A–C). CD41 T cells were mainly
present in the T area, but were also observed within germi-
nal centers (Fig. 5, D–F). Moreover, a light zone contain-
ing strongly VSV-binding germinal center B cells could be
distinguished from a dark zone containing sIg-negative B
lymphocytes (Fig. 5, G–I). It should be noted that VSV-
specific plasma cells were detectable in the spleens of
CD282/2 mice (Fig. 5 J) and that CD282/2 mice could still
Figure 2. Immunocytometric analysis of B cell populations in the bone
marrow (left) and spleen (right) of 129/J, SEK11/1 chimeric, SEK12/2
chimeric, and RAG22/2 mice. Cells were isolated from 6-wk-old mice
and double stained using anti-B220 (PE) and anti-CD43 (FITC), or anti-
B220 (PE) and anti-sIgM (FITC). Percentages of positive cells within a
quadrant are indicated. Note the partial block in the maturation from
CD431B2201 pro–B cells to CD432B2201 pre–B cells in the bone mar-
row and the reduced number of sIgM1 B cells in the spleen of SEK12/2
chimeric mice (see also Table 1). 10,000 viable cells were collected and
analyzed on a FACScanÒ. Total cell numbers were: 129/J bone marrow
(total lymphoid cells isolated from one femur), 7.9 3 106; 129/J spleen,
4.1 3 107; SEK11/1 chimeric bone marrow, 8.3 3 106; SEK11/1 chi-
meric spleen, 3.1 3 107; SEK12/2 bone marrow, 7.7 3 106; SEK12/2
chimeric spleen, 3.9 3 107; RAG22/2 bone marrow, 9.8 3 106;
RAG22/2 spleen, 1.3 3 107.
Figure 3. PCR analysis for
SEK1 mutant and wild-type al-
leles in total bone marrow and
sorted B2201CD431 and B2201
CD432 bone marrow cells from
SEK12/2 and SEK11/1 chimeric
mice. Bone marrow cells were
double stained with anti-B220
(PE) and anti-CD43 (FITC) and
populations were sorted using a
FACSÒ power sorter (Coulter).
Postsorting purity of CD431
B2201 and B2201CD432 cells
was  .98%. Purified B cell popu-
lations (5 3 104 cells) were sub-
jected to PCR analysis as de-
scribed in Materials and Methods. Total bone marrow cells (105) (Bone
marrow) from 129/J, SEK12/2 chimeric, SEK11/1 chimeric, and RAG22/2
mice are shown as controls.947 Nishina et al.
produce, albeit at low levels, neutralizing IgG Abs (Table
2). These data show that SEK12/2RAG22/2 mice can
mount biologically relevant responses against VSV and that
SEK1 has no apparent role in CD28-dependent, virus-spe-
cific germinal center formation.
SEK1-independent SAPK/JNK Activation in Peripheral T
Cells. Although SEK12/2 peripheral T cells displayed re-
duced proliferation and IL-2 production in response to
CD28 in vitro, SEK1 expression was not an absolute re-
quirement for T cell activation in vivo. Thus, similar to our
data that shows that SEK1-dependent and SEK1-indepen-
dent signaling pathways for SAPKs/JNKs activation exist in
ES cells (23), it was possible that a SEK1-independent
pathway for SAPK/JNK activation was operational in T
cells. To test this hypothesis, we examined SAPKs/JNKs
activation in peripheral T cells and thymocytes in response
to PMA/Ca21 ionophore (Fig. 6 A), which mimic TCR–
CD3 and CD28-mediated signal transduction (29,45).
SAPK activation, i.e., SAPK-mediated c-Jun phosphorylation,
was observed in SEK11/1, but not in SEK12/2, thymocytes,
indicating that SEK1 is the crucial genetic regulator of
PMA/Ca21 ionophore–triggered activation of SAPKs/JNKs
in thymocytes (23; Fig. 6 A). Surprisingly, using the same
PMA/Ca21 ionophore activation regimen, SAPK activa-
tion was observed in peripheral lymph node T cells from
both SEK12/2 and SEK11/1 mice (Fig. 6 A). The levels of
SAPKs (JNK1 and JNK2) expression were comparable among
SEK12/2RAG22/2 and SEK11/1RAG22/2 thymocytes and
peripheral T cells (Fig. 6 B), suggesting that the observed
differences in PMA/Ca21 ionophore–mediated SAPK acti-
vation in SEK12/2 thymocytes versus SEK12/2 lymph node
T cells were not the result of alterations in SAPK expres-
sion. Our data that SAPKs are activated in peripheral T
cells, but not in thymocytes, from SEK12/2 chimeras in re-
sponse to the same stimulus PMA/Ca21 ionophore indicate
Figure 4. B cell activation and immunoglobulin production in SEK12/2
mice. (A) Activation of splenic B cells. Purified splenic B cells (105/well)
from SEK12/2 (shaded bars) and SEK11/1 (open bars) control mice were
seeded in medium containing no added stimulus (Control), soluble anti-
Igm Ab (10 mg/ml, clone B76), IL-4 (10 U/ml), soluble anti-CD40 (1
mg/ml), IL-4 (10 U/ml) plus soluble anti-CD40 (1 mg/ml), and 10 mg/ml
LPS (LPS). After 24 h, the cells were pulsed for 12 h with 1 mCi [3H]thy-
midine/well. The experiment shown is one of four experiments in which
conditions for stimulation varied (time, cell concentration, concentration
of activators). No significant differences (Student’s t test; p . 0.05) were
observed in the [3H]thymidine uptake between SEK12/2 and SEK11/1 B
cells in response to any of these conditions. [3H]thymidine uptake is
shown in cpm 6 SD. (B) SEK12/2 mice produce normal levels of serum
immunoglobulin subclasses. Sera were collected from two individual
6-wk-old SEK12/2 (shaded bars) and two individual 6-wk-old SEK11/1
(open bars) chimeric mice. The concentrations of Ig subclasses are shown
in mg/ml and were determined by ELISA. Standard deviations were ,25
mg/ml.
Table 2. Neutralizing Anti-VSV Response in SEK12/2 and 
CD282/2 Mice
Titers of neutralizing activities (2 log 2)*
Day 4 Day8 Day12
Genotype IgM IgG IgG IgG
SEK11/1 9 ,19 1 1
10 ,19 1 1
SEK12/2 9 ,17 1 0
10 ,18 1 1
CD282/2 9 ,12 2
9 , 12 3
* Sera were isolated from mice after intravenous infection with VSV
(2 3 106 PFU). Neutralizing IgM and IgG titers were determined as
described in Materials and Methods. Titers represent twofold dilution
steps of sera starting with 1:40.948 SEK1 in CD28 Costimulation
that signaling pathways for SAPK/JNK activation are de-
velopmentally regulated.
IL-2 Production in SEK12/2 Thymocytes. The results in
SEK12/2 lymph node T cells indicated that SEK1 has a
role in CD28-mediated costimulation for proliferation and
IL-2 production in peripheral T cells and that lymph node
T cells use a second signaling pathway for SAPK activation
that is independent of SEK1. Since this second signaling
pathway is not operational in SEK12/2 thymocytes, we
tested proliferation and IL-2 production of SEK12/2 thy-
mocytes in response to PMA/Ca21 ionophore and CD3/
CD28 activation. Surprisingly, SEK12/2RAG22/2 thy-
mocytes proliferated and made IL-2 after PMA/Ca21 iono-
phore and CD3/CD28 stimulation, albeit at significantly
Figure 5. Germinal center formation in SEK12/2 and CD282/2 mice. SEK12/2, SEK11/1, and CD282/2 mice were immunized with VSV Indiana (2 3
106 PFU). Serial spleen sections were processed for immunostaining 12 d after immunization as described in Materials and Methods. Original magnifica-
tions: (A–I) 200; (J) 400. (A–C) PNA1 cells localize to germinal centers and the marginal zone in (A) SEK11/1 and (B) SEK12/2 mice. (C) Absence of
germinal center formation and germinal center PNA1 B cells in VSV-infected CD282/2 mice. Some PNA1 B cells are present in the marginal zone and
the red pulp of CD282/2 mice. (D–F) CD41 T cells localize mainly to the periarteriolar lymphatic sheaths, but are also present in germinal centers and
the follicular mantle zone in (D) SEK11/1 and (E) SEK12/2 mice. (F) CD41 T cells in the spleen of VSV-infected CD282/2 mice. (G–I) VSV-specific B
cells in germinal centers of (G) SEK11/1 and (H) SEK12/2 mice. Note the presence of VSV-specific B cells outside the germinal centers that show cyto-
plasmic staining. These cells are VSV-specific plasma cells (44). (I) VSV-specific germinal centers are absent in VSV-infected CD282/2 mice. (J) VSV-
specific plasma cells in VSV-infected CD282/2 mice.949 Nishina et al.
lower levels compared to SEK11/1RAG22/2 thymocytes
(Fig. 7). These data further confirm that SEK1 relays CD28
costimulatory signals to IL-2 production in T cells. How-
ever, these results in thymocytes also indicate that CD28
costimulation and PMA/Ca21 ionophore–triggered signal-
ing pathways exist that can mediate proliferation and IL-2
production independently of SAPK activation.
Discussion
SAPKs/JNKs are activated in response to many cellular
stresses such as osmolarity changes, metabolic poisons, DNA-
damaging agents, heat shock, ischemia/reperfusion injury, UV-,
or g-irradiation (9, 10, 13, 14, 18, 25). The dual specificity ki-
nase SEK1 (JNK kinase/MKK4) has been identified as a potent
and direct activator of SAPKs/JNKs in vitro and in cell lines
in vivo (20–22). Although it has been shown genetically that a
second SAPK activator, SEK2, exists (23), SEK1 is the only
cloned kinase that can directly activate SAPKs/JNKs (11, 12).
In addition to the induction of SAPK/JNK activity by
many types of cellular stresses (10), SAPKs/JNKs are acti-
vated in response to certain growth factors, heterotrimeric
G proteins, phorbol esters, CD40 cross-linking, and CD28-
mediated costimulation in T cells (9, 10, 14, 29–32, 54).
Moreover, activation of SAPKs/JNKs leads to phosphory-
lation of c-Jun and activation of Jun/Fos heterodimeric
AP-1 complexes, which are involved in the coordinate ac-
tivation of IL-2 transcription (10, 19, 20, 55). In T cells, li-
gation of the TCR results in rapid activation of the
Ras®Raf®MEK®MAPK signaling cascade (11, 56).
However, activation of the MAPK cascade is not sufficient
for effective IL-2 production and cell proliferation for
which T cells require a second signal (35). Recently, it has
been shown that coordinate stimulation of the TCR–CD3
complex and the costimulatory receptor CD28 correlates
with the activation of SAPKs/JNKs, phosphorylation of
c-Jun, and induction of AP-1 activity (29). These bio-
Figure 5. Continued
Table 3. Quantification of Germinal Centers in SEK12/2 and 
CD282/2 Mice
No. of germinal centers*
Genotype PNA1 VSV specific
SEK11/1 53 6 4.4 51 6 5.0
SEK12/2 55 6 2.0 49 6 2.4
CD282/2 00
* The mean germinal center numbers (6 SD) per section were deter-
mined on at least eight different spleen section levels from two individ-
ual mice/group. PNA-positive and VSV-specific germinal centers were
visualized as described in Materials and Methods.950 SEK1 in CD28 Costimulation
chemical data indicated that T cells use two distinct signal-
ing cascades for antigen-specific activation, TCR-triggered
MAPK activation and TCR–CD28-induced activation of
SAPKs/JNKs. Importantly, it has been suggested that fail-
ure to activate SAPKs/JNKs in T cells might result in
clonal anergy and the induction of immunological toler-
ance (36, 37).
Our demonstration of defective IL-2 production and
proliferation in SEK12/2 T cells in response to CD28 co-
stimulation and PMA/Ca21 ionophore provides the first
genetic evidence that the stress signaling kinase SEK1 is a
downstream effector involved in TCR and CD28 corecep-
tor signaling. However, the impairments of proliferation
and IL-2 production were not complete, and a strong acti-
vation signal via the TCR–CD3 complex alone triggered
normal proliferation of SEK12/2 T cells. Thus, although
SEK1 appears to be necessary for adequate IL-2 production
and proliferation in T cells, another activator(s) can com-
pensate for the SEK1 deficiency in peripheral T cells. This
hypothesis is in line with our biochemical data on SEK1-
independent activation of SAPKs/JNKs in lymph node T
cells in response to PMA/Ca21 ionophore stimulation. In-
terestingly, this second pathway for SAPK/JNK activation
is only operational in peripheral T cells but not in thy-
mocytes, indicating that signaling pathways for SAPK/JNK
activation are developmentally regulated in T cells. It has
also been shown that proliferation and IL-2 production are
normal in c-Jun2/2RAG22/2 T cells, suggesting that not
only c-Jun, but also other Jun family members, i.e., JunD
and JunB, may have a role in T cell activation (57). The
exact role of distinct SAPK/JNK activators, SEK1 versus
SEK2, and of different Jun family transcription factors in
CD28-mediated IL-2 production and T cell activation
needs to be determined.
SEK12/2RAG22/2 thymocytes failed to induce SAPK/
JNK in response to PMA/Ca21 ionophore. Interestingly,
SEK12/2RAG22/2 thymocytes still proliferated and pro-
duced IL-2 after PMA/Ca21 ionophore and CD3/CD28
stimulation, albeit at significantly lower levels compared to
SEK11/1RAG22/2 thymocytes. These data further con-
firmed that SEK1 relays CD28 costimulatory signals to IL-2
production in T cells. However, these results also indicate
that, at least in thymocytes, CD28 and PMA/Ca21 iono-
phore–triggered signaling pathways exist that can mediate
proliferation and IL-2 production independently of SAPK
activation. Besides activation of SEK1 and SAPKs/JNKs,
additional downstream effectors for CD28 signaling have
been identified including PI39K, PLCg1, Raf-1, and Vav
(see review in reference 58). In particular, it has been
shown that Vav, Ras, and the Vav-associated tyrosine
phosphoprotein SLP76 can cooperate to induce nuclear
factor of activated T cells activity and IL-2 secretion after
activation of the TCR (59–61). Nevertheless, a growing
Figure 6. Activation of SAPKs/JNKs in thymocytes (top) and lymph
node T cells (bottom). (A) Thymocytes (top) and purified mesenteric
lymph node T cells (bottom) were isolated from SEK11/1 and SEK12/2
mice and cells (5 3 106/lane) were activated with PMA (50 ng/ml) plus
Ca21 ionophore (1 mg/ml) for 0 and 10 min as described in Materials and
Methods. SAPK/JNK were immunoprecipitated and assayed for in vitro
kinase activity using glutathione-S-transferase–c-Jun as a substrate. Pe-
ripheral T cells were purified using affinity columns and purity of CD31
T cells was .98% as determined by cytometry. One result representative
of three independent experiments is shown. (B) Western blotting for p46
and p54 SAPK/JNK isoform expression in SEK11/1 (1/1) and SEK12/2
(2/2) chimeric thymocytes and purified lymph node T cells. Thy-
mocytes (106/lane) and lymph node cells (5 3 106/lane) were blotted for
SAPK expression as described in Materials and Methods (23).
Figure 7. Proliferation (A) and IL-2 production (B) of SEK12/2
(shaded bars) and SEK11/1 chimeric (open bars) thymocytes. Thymocytes
(105 T cells/well) were activated with plate-bound anti–CD3-e (1 mg/
ml) and soluble anti-CD28 Abs (100 ng/ml; CD3-e 1 CD28) or PMA
(12.5 ng/ml) plus Ca21 ionophore (100 ng/ml) (PMA 1 Ca). Rabbit
anti–hamster Ig-coated plates without addition of anti–CD3-e/CD28 Abs
are shown as controls. After 48 h of stimulation, proliferation was deter-
mined by [3H]thymidine uptake, and IL-2 production was determined by
ELISA. Data of triplicate cultures 6 SD are shown. The low IL-2 pro-
duction of thymocytes after PMA/Ca21 ionophore stimulation is due the
fact that PMA/Ca21 ionophore also induces proliferation of
CD42CD82TCR2 thymocytes, the majority of which does not produce
IL-2. One result representative of three independent experiments is
shown.951 Nishina et al.
body of evidence suggests that Vav functions as a guanine
nucleotide (GDP/GTP)-exchange factor for members of the
Rho family of small GTPases that regulate activation of the
SAPK pathway (62–64). Whether Vav can relay TCR-medi-
ated signals to proliferation and IL-2 production indepen-
dently of SAPK activation needs to be determined.
Similar to the reported reduction in CD41CD81 thymocyte
numbers (23), SEK12/2RAG22/2 chimeric mice had a
partial block in the transition from B2201CD252CD431
pro–B cells to B2201CD251CD432  pre–B cells in the
bone marrow. This effect was due to the SEK1 mutation
and not due to a low chimerism and contribution of
RAG22/2 cells to the CD431 population (Fig. 3). How-
ever, splenic B cells from SEK12/2RAG22/2 chimeras dis-
played normal proliferation in reponse to Igm, CD40, IL-4,
or LPS activation. Moreover, basal Ig levels of all subclasses
and IgG class switching after viral challenge were compara-
ble between SEK12/2 and SEK11/1 B cells. These results
imply that SEK1 has a role in early differentiation of B cell
precursors, but SEK1 is not necessary for proliferation and
Ig secretion of peripheral B cells.
The prominent expression of the GCK within germinal
centers (34) and activation of SAPK through GCK (33)
suggested that the GCK/SAPK pathway might be impor-
tant for B cell differentiation within germinal centers.
Moreover, mice lacking CD28 (51) or CD40 (52, 53) do not
develop germinal centers. Both CD28- and CD40-trig-
gered signaling cascades lead to the activation of SAPKs/
JNKs (10, 29, 31, 32). Although SEK1 is an important
component of CD28-mediated IL-2 production and T cell
proliferation and VSV-specific germinal center formation is
dependent on CD28 expression (Fig. 5), our results clearly
indicate that SEK1 is not involved in germinal center for-
mation in response to VSV infection. SEK1-independent
activation of peripheral T cells might explain the fact that
SEK12/2 chimeric mice can mount CD28 costimulation
dependent responses against VSV infections. Since multiple
downstream effectors for CD28 signaling have been identi-
fied including SEK1/SAPK, PI39K, PLCg1, Vav, or Raf-1
kinase (see reviewed in reference 58), it is possible that
CD28-mediated signaling for IL-2 production and CD28-
dependent signaling for germinal center formation are bio-
chemically different.
Conclusion. SEK1 (MKK4, JNK kinase) is a direct acti-
vator of stress-activated protein kinases (SAPK/JNK) in re-
sponse to CD28 costimulation, CD40 ligation, and activa-
tion of the GCK. SEK12/2RAG22/2 chimeric mice have a
partial block in B cell maturation, but peripheral B cells
displayed normal responses to IL-4, IgM, and CD40 cross-
linking and normal IgG class switching of neutralizing Abs
after viral challenge. T cells from chimeric mice showed
decreased proliferation and IL-2 production in response to
CD28 costimulation and PMA/Ca21 ionophore activation.
Although CD28 was absolutely crucial to generate VSV-
specific germinal centers, SEK12/2 chimeras made normal
germinal centers in response to VSV. Interestingly, PMA/
Ca21 ionophores’ stimulation, which mimic TCR–CD3 and
CD28-mediated  signal transduction, induced SAPK/JNK
activation in peripheral T cells, but not in thymocytes,
from SEK12/2 mice. These results demonstrate that signal-
ing pathways for SAPK activation are developmentally reg-
ulated in T cells. Although SEK12/2 thymocytes failed to
induce SAPK/JNK in response to PMA/Ca21 ionophore,
SEK12/2RAG22/2 thymocytes proliferated and made IL-2
after PMA/Ca21 ionophores and CD3/CD28 stimulation, al-
beit at significantly lower levels compared to SEK11/1
RAG22/2 thymocytes, indicating that CD28 costimulation
and PMA/Ca21 ionophore–triggered signaling pathways
exist that can mediate proliferation and IL-2 production in-
dependently of SAPK activation. These data provide the
first genetic evidence that SEK1 is an important effector
molecule that relays CD28 signaling to IL-2 production
and T cell proliferation.
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